Catalytically activating mutations in Ptpn11, which encodes the protein tyrosine phosphatase SHP2, cause 50% of Noonan syndrome (NS) cases, whereas inactivating mutations in Ptpn11 are responsible for nearly all cases of the similar, but distinct, developmental disorder Noonan syndrome with multiple lentigines (NSML; formerly called LEOPARD syndrome). However, both types of disease mutations are gain-of-function mutations because they cause SHP2 to constitutively adopt an open conformation. We found that the catalytic activity of SHP2 was required for the pathogenic effects of gain-of-function, disease-associated mutations on the development of hydrocephalus in the mouse. Targeted pan-neuronal knockin of a Ptpn11 allele encoding the active SHP2 E76K mutant resulted in hydrocephalus due to aberrant development of ependymal cells and their cilia. These pathogenic effects of the E76K mutation were suppressed by the additional mutation C459S, which abolished the catalytic activity of SHP2. Moreover, ependymal cells in NSML mice bearing the inactive SHP2 mutant Y279C were also unaffected. Mechanistically, the SHP2 E76K mutant induced developmental defects in ependymal cells by enhancing dephosphorylation and inhibition of the transcription activator STAT3. Whereas STAT3 activity was reduced in Ptpn11 E76K/+ cells, the activities of the kinases ERK and AKT were enhanced, and neural cell-specific Stat3 knockout mice also manifested developmental defects in ependymal cells and cilia. These genetic and biochemical data demonstrate a catalytic-dependent role of SHP2 gain-of-function disease mutants in the pathogenesis of hydrocephalus.
INTRODUCTION
Ptpn11 is ubiquitously expressed and encodes SH2 domain-containing phosphatase 2 (SHP2), a protein tyrosine phosphatase (PTP) implicated in multiple cell signaling processes, including the rat sarcoma (RAS)-extracellular signal-regulated kinase (ERK), Janus kinasesignal transducer and activator of transcription (STAT), phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB; also known as AKT), mouse target of rapamycin (mTOR), and nuclear factor B pathways (1, 2) . Under baseline conditions, it is self-inhibited by hydrogen bonding of a loop on the back side of the N-terminal SH2 (N-SH2) domain with the deep pocket of the PTP domain (3, 4) . SHP2 becomes activated upon binding to signaling partners that contain phosphorylated tyrosine residues, playing an overall positive role in transducing signals initiated from receptor and cytosolic kinases, particularly in the RAS-ERK pathway (1, 2) . However, the signaling mechanisms of SHP2 are still not well understood; accumulating evi dence suggests that SHP2 functions in cell signaling in both catalytic-dependent and catalytic-independent manners (5) (6) (7) (8) . Its roles that do not depend on catalytic activity are likely to involve SHP2 acting as a scaffolding protein.
The critical role for SHP2 in cell signaling is further underscored by the direct association of mutations in this phosphatase with human diseases. Catalytically activating heterozygous germ-line mutations in Ptpn11 are associated with 50% of cases of Noonan syndrome (NS) (9) , a developmental disorder characterized by congenital heart disease, dysmorphic facial and chest features, proportionate short stature, and intellectual disability (10) . Furthermore, somatic mutations of Ptpn11 are found in various childhood leukemias (11) (12) (13) (14) . Ptpn11 mutations identified in NS and in leukemias typically result in amino acid changes in the region between the N-SH2 and PTP domains, which disrupt the autoinhibitory interaction and cause SHP2 to adopt an open conformation, leading to hyperactivation of SHP2 catalytic activity (9, 11, 15) . Germ-line heterozygous mutations in Ptpn11 are also highly associated (>90%) with another rare developmental disorder called NS with multiple lentigines (NSML; formerly known as LEOPARD syndrome), which is characterized by multiple lentigines, cardiac abnormalities, facial dysmorphism, retardation of growth, and sensorineural deafness (16, 17) . In contrast to the NS mutations, Ptpn11 mutations identified in NSML eliminate the catalytic activity of SHP2 due to changes in the active site amino acid residues that are critical for hydrolyzing activity (18) . However, both NS and NSML mutations cause SHP2 to adopt an open conformation and enhance SHP2 interactions with signaling partners despite having opposing effects on catalytic activity (9, (18) (19) (20) (21) , resulting in gain of function of SHP2. How allelic variants of Ptpn11 with opposing enzymatic activities lead to similar, yet distinct, syndromic disorders remains poorly understood (22) . Here, we sought to determine the cellular and molecular mechanisms underlying the pathogenic effects of NS-and NSMLassociated Ptpn11 mutations in brain development. Our results suggest that Ptpn11 disease mutations induce hydrocephalus in a manner that depends on the catalytic activity of SHP2.
the intramolecular interaction that mediates SHP2 autoinhibition (11 (24, 25) with Nestin-Cre + mice (26) , which express Cre in neural precursor cells beginning at embryonic day 10.5 (E10.5). After heterozygous induction of the SHP2 E76K mutant, SHP2 phosphatase activity in the brain increased by more than threefold compared to that in the brain of wild-type mice (Fig. 1A) . No brain tumors developed in these animals during a 15-month follow-up, suggesting that Ptpn11 activating mutations found in human brain tumors are not driving mutations. Forty percent of Ptpn11 E76K/+ /Nestin-Cre + mice died within 2 months of birth (Fig. 1B) . They displayed obvious dome-shaped heads (Fig. 1C) , and magnetic resonance imaging of live animals suggested that these mice had substantially enlarged cerebral ventricles ( fig. S1A ). Autopsy revealed frank hydrocephalus of varying severity; specifically, the cerebral ventricles were filled with excess cerebrospinal fluid (Fig. 1C) . Histopathological examination of brain tissues showed that the cerebral cortex was much thinner and that lamination of the cortex was compromised, as compared to control tissues (Fig. 1D) S1B ). Despite this apparent reduction in anxiety, they manifested hyperactivity, as indicated by an increase in the distance traveled ( fig. S1C) , as compared to control mice. In addition, these mutant mice showed impaired motor function in grip strength tests ( fig. S1D ) and reduced hanging times in wire hang tests ( fig. S1E ). These aberrant behavior profiles verify developmental defects in the central nervous system in mice expressing SHP2 E76K .
Ptpn11
E76K reduces proliferation but enhances glial differentiation in neural stem and progenitor cells 
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brain tissues and found that, relative to Ptpn11 +/+ /Nestin-Cre + mice at the same developmental stage, the number of neurons decreased and the number of astrocytes markedly increased in both the cortex ( Fig. 2A and fig. S2A ) and the hippocampus (Fig. 2B and fig. S2B ). We observed no obvious defects in the cerebellum ( fig. S2C ). The cell composition and the structure of the mutant cortices were relatively normal at the neonatal stage ( fig. S2D) , suggesting that the abnormal composition of neural cells in the adult mutant mice might be associated with indolent hydrocephalus, which was previously shown to cause enhanced gliogenesis and reduced neurogenesis (27) . Specificity protein 8 (Sp8) is a member of the Sp1 family of zinc finger transcription factors that is enriched in migrating neuroblasts of the subventricular zone (SVZ) (28) (Fig. 2C ). This observation raised the possibility that NSPC activities might be altered by the Ptpn11 E76K mutation. To test this possibility, we performed neurosphere assays for the cortices isolated from E14.5 embryos. Although cortices from Ptpn11 E76K/+ mice and wild-type mice yielded similar total numbers of primary and secondary neurospheres ( fig. S3A ), the actual size of mutant neurospheres was much smaller (Fig. 2D) , and proliferation of mutant neurosphere cells was decreased, as compared to controls (Fig. 2E) 
in apoptosis ( fig. S3B ). However, cell cycle analyses showed that the percentage of Ptpn11 E76K/+ neurosphere cells in the G 0 phase doubled, whereas the percentage of cells in the G 1 and S, G 2 , or M phases decreased significantly (Fig. 2F) . Furthermore, mutant neurosphere cells tended to spontaneously differentiate. Increased numbers of adherent glia-like cells developed in Ptpn11 E76K/+ neuro sphere cells during culture conditions that favored maintenance of NSPCs over differentiation (Fig. 2D) .
Hydrocephalus induced by Ptpn11
E76K results from aberrant development of ependymal cells To identify the cellular mechanism underlying the hydrocephalus phenotype in Ptpn11 E76K/+ /Nestin-Cre + mice, we examined the cerebrum, the cerebellar tonsils, and the cerebrospinal circulation system but found no obstructions. We also carefully examined choroid plexuses, which are responsible for production of cerebrospinal fluid (29, 30) , but no structural changes were observed there either. Scanning electron microscopy revealed that the cilia of ependymal cells, which play an essential role in the transport of cerebrospinal fluid (29, 30) , developed aberrantly in Ptpn11 E76K/+ /Nestin-Cre + mice; they were much shorter and apparently disorganized, as compared to those from control mice (Fig. 3A) . Moreover, there was a reduction in the number of cells that stained positive for the ependymal cell marker Forkhead box J1 (FoxJ1) (Fig. 3B ). The decrease in ependymal cells and the defects in ependymal cilia (marked by acetyl -tubulin) ( 
Ptpn11 E76K decreases STAT3 activity and enhances ERK and AKT signaling
We next investigated the molecular mechanisms for the pathogenic effects of the Ptpn11 E76K mutation. Consistent with the positive role that SHP2 plays in the RAS signaling pathway, ERK activity was increased in the cortex and hippocampus of Ptpn11 (31, 32) . Unexpectedly, we observed no change in cell proliferation in this region, as measured by phosphorylated histone H3 staining ( fig. S5 ). Given that basic fibroblast growth factor (bFGF) plays an essential role in neural progenitor cell survival and proliferation, we examined bFGF signaling in neurosphere cells. Although the abundance of the bFGF receptor (bFGFR) was comparable in the mutant and control cells ( fig. S6A ), bFGF-induced ERK activation was increased in the cells isolated from Ptpn11 E76K/+ mice ( Fig. 4B and fig. S6B ). In addition, AKT activation was enhanced in these mutant cells. Furthermore, we found that ciliary neurotrophic factor (CNTF), which promotes the survival and growth of neurons, induced similar increases in ERK and AKT activities in the mutant and control cells ( Fig. 4C and fig. S6C ). In contrast to these effects on ERK and AKT, cells in neurospheres derived from Ptpn11 E76K/+ mice showed a decrease in STAT3 activity in response to CNTF or bFGF activation ( Fig. 4D and fig. S6D ). Tyrosine phosphorylation of STAT3 was markedly decreased in ependymal cells in Ptpn11 E76K/+ mice (Fig. 4E) . Because STAT3 is a substrate of SHP2 (33, 34) , the diminished STAT3 activity was likely caused by enhanced dephosphorylation of STAT3 by hyperactive SHP2 E76K .
Depletion of STAT3 results in developmental defects in ependymal cilia
To test the possibility that diminished STAT3 activity might be responsible for the aberrant development of ependymal cells and hydrocephalus in Ptpn11 ). These animals die shortly after birth due to defective heart development and respiratory failure (34) . We were able, however, to examine the brains of Stat3 fl/fl /Nestin-Cre + neonates. These newborn pups did not exhibit obvious enlargement of the ventricular system, and the cerebrum appeared normal (Fig. 5A ). However, immunostaining of brain sections revealed clear defects in ependymal cilia and a reduced number of ependymal cells in the mutant mice (Fig. 5B) . Moreover, NSPCs from Stat3 knockout newborn pups failed to differentiate into ependymal cells in culture (Fig. 5C ), similar to NSPCs from Ptpn11 E76K/+ pups. The self-renewal capability of Stat3 knockout NSPCs was also reduced (Fig. 5, D and E) , implying that the decreased proliferation of Ptpn11 E76K/+ NSPCs (Fig. 2 , D and E) is likely due to diminished STAT3 activity. In addition, although the number of neurons was not changed, the number of astrocytes was increased in the cerebral cortex and hippocampus of the Stat3 conditional knockout neonates (Fig. 5F ).
The Ptpn11 E76K mutation affected several signaling pathways. To further determine which altered pathway was responsible for the defective ependymal cell differentiation of Ptpn11 E76K/+ /Nestin-Cre + NSPCs, we treated these cells with mitogen-activated protein kinase kinase 1 (MAPKK1; also known as MEK1) and PI3K inhibitors. Because MAPKK1 and PI3K function upstream of ERK and AKT, respectively, inhibiting their activity should counteract the hyperactivation of ERK and AKT. Inhibiting neither MAPKK1 nor PI3K activity with PD98059 or LY294002, respectively, rescued ependymal cell differentiation in explants from Ptpn11 E76K/+ /Nestin-Cre + pups (Fig. 6, A and B) . By contrast, treatment with the SHP2 inhibitor #220-324 (35) largely rescued ependymal cell development, increased STAT3 activity, and decreased ERK and AKT activities (Fig. 6 , C and D) in explants from Ptpn11 E76K/+ pups. These rescue data provide additional evidence that aberrant ependymal cell development and hydrocephalus manifested by Ptpn11 E76K/+ /Nestin-Cre + mice were attributable to diminished STAT3 activity rather than increased ERK or AKT activity.
The pathological effects of Ptpn11 disease mutations in hydrocephalus development depend on increased catalytic activity of SHP2 To verify that Ptpn11 mutations induce aberrant brain development through increased SHP2 catalytic activity, we examined an NS mouse model ubiquitously expressing the SHP2 activating mutation D61G (Ptpn11 D61G/+ ) (36), which is less catalytically active than the E76K mutation (11, 15) . None of the Ptpn11 D61G/+ mice displayed overt hydrocephalus; however, ependymal cilia were found to be abnormal similarly to, but to a lesser degree than, those in Ptpn11 E76K/+ mice. Ptpn11 D61G/+ mice showed ependymal cilia defects only on the third ventricular walls (Table 1 and fig. S7 ). These observations suggest that the pathological effects of Ptpn11 activating mutations in the development of hydrocephalus correlate with the increased catalytic activity of mutant SHP2, although a potential systematic effect on the phenotypes cannot be completely excluded because Ptpn11 E76K was expressed in neural tissues, whereas Ptpn11 D61G was expressed in the whole body. In addition, Ptpn11 D61G/+ mice were the F4 generation from backcrosses with C57BL/6 mice, whereas Ptpn11 E76K/+ mice were on pure C57BL/6 background; therefore, potential effects of the genetic backgrounds on the phenotypes cannot be completely excluded.
We next extended our studies to examine the effects of mutations that catalytically inactivate SHP2. To do this, we used the NSML mouse model in which the most common mutation found in NSML patients, Y279C, is ubiquitously expressed (Ptpn11 (20) . This is an inactivating mutation because it affects a conserved residue important for PTP catalysis. In contrast to Ptpn11 D61G/+ NS mice, none of the 17 Ptpn11 Y279C/+ NSML mice (F4 generation from backcrosses with C57BL/6 mice) we examined developed hydrocephalus, nor did we observe defects in ependymal cilia (Table 1 and fig. S7 ).
Inspired by the above observations and also to further confirm that Ptpn11 activating mutations induce hydrocephalus through enhanced catalytic activity of SHP2, we generated Ptpn11 E76K,C459S double-mutant knockin mice by gene targeting ( fig. S8 , A to C). The Cys residue at amino acid position 459 in the catalytic core is critical for the enzymatic activity of SHP2 (37, 38) . Replacement ) developed hydrocephalus during a 15-month follow-up (Table 2) . We also assessed Ptpn11 E76K,C459S/+ NSPCs by the neurosphere assay; neither the number nor the size of the primary, secondary, and tertiary neurospheres derived from Ptpn11 E76K,C459S/+ mice showed significant differences from wild-type controls (Fig. 7A) . The growth of these double-mutant neurosphere cells was essentially normal (Fig. 7B) . Moreover, the ability of Ptpn11 E76K,C459S/+ NSPCs to differentiate into ependymal cells in vitro was restored (Fig. 7C) , and the ependymal cilia in Ptpn11 E76K,C459S/+ mice developed without noticeable defects (Fig. 7D) . Cell signaling, especially STAT3 activity, in Ptpn11 E76K,C459S/+ double-mutant neurosphere cells was restored to that of controls (Fig. 7E and fig. S8, D to F) . The ability of the inactivating C459S mutation to rescue ependymal cell development in double mutants reaffirmed that Ptpn11 activating mutations in NS induced hydrocephalus in a catalytically dependent manner.
DISCUSSION
Germ-line activating and inactivating mutations of Ptpn11 (SHP2) are associated with two highly related developmental disorders, NS and NSML. Here, we demonstrate that Ptpn11 mutations affect brain development in a manner that depends on the catalytic activity of 
SHP2. Neural expression of the activating mutation E76K in mice (Ptpn11

E76K/+
) caused hydrocephalus due to aberrant development of ependymal cells and their cilia, whereas ubiquitous expression of the inactivating mutation Y279C in mice (Ptpn11 Y279C/+ ) did not induce hydrocephalus and had no effect on the ependymal cells. In addition, the severity of hydrocephalus caused by Ptpn11 activating mutations correlated with the potency of the enhanced SHP2 catalytic activity. The pathogenic effect of the activating mutation E76K in Ptpn11 was completely abolished by the addition of the catalytically inactivating mutation C459S. None of the Ptpn11 E76K,C459S/+ double-mutation knockin mice developed hydrocephalus. Given that Ptpn11 activating mutations induced hydrocephalus but inactivating mutations did not, this phenotype may be used for differential diagnosis or prognosis, or both, in NS and NSML patients. Hydrocephalus has been observed in NS patients (39) (40) (41) . Because hydrocephalus development depends on increased catalytic activity of mutant SHP2, our mouse genetics data additionally imply that increased catalytic activity of mutant SHP2 may be a useful therapeutic target for controlling the progression of hydrocephalus in NS patients. Ptpn11 disease mutations appear to perturb neural cell function and brain development through various signaling pathways. SHP2 is involved in several cell signaling processes, and it can also function at multiple steps in a single pathway (1, 2) . This phosphatase has functions that depend on its catalytic activity and other functions that depend only on its ability to interact with other proteins and act as a scaffolding protein. SHP2 has been shown to play multiple roles in NSPCs, corticogenesis, astroglia cell fate decisions, and oligodendrocyte development in the telencephalon (42) (43) (44) . NS mutations in SHP2 cause aberrant lineage specification in cultured NSPCs and in neonatal mice (45) . Our data in this report provide insights into how Ptpn11 activating mutations can cause hydrocephalus, specifically by affecting the development of ependymal cells from NSPCs. The potency of the mutations in activating SHP2 catalytic activity correlates with the developmental defects in ependymal cells and the hydrocephalus phenotype. Therefore, "weaker" SHP2 activating mutations might not have the necessary threshold of SHP2 catalytic activity to induce hydrocephalus but may still have an impact in other central nervous system cell lineages.
Activating mutations in Ptpn11 enhance growth factor-induced ERK and AKT activities in neurosphere cells, which may account for their accelerated or spontaneous differentiation toward the glial lineage. This perturbation in neurogenesis and gliogenesis is likely responsible for the aberrant behavior of Ptpn11 E76K knockin mice. However, the increased ERK and AKT activities do not explain the reduced growth rate of Ptpn11 E76K/+ neurosphere cells. Rather, suppression of STAT3 activity in response to catalytically hyperactive SHP2 may account for this pathological effect. The inhibition of STAT3 possibly also contributes to the defects in ependymal cells and cilia in these mutant mice. This notion is supported by the fact that Stat3 knockouts (Stat3 E76K,C459S/+ double-mutant mice also supports that diminished STAT3 activity is likely responsible for the developmental defects in ependymal cells and hydrocephalus associated with Ptpn11 (SHP2) activating mutations. Nevertheless, it remains to be determined how diminished STAT3 activity caused a decrease in the ependymal cell differentiation from NSPCs and the malformation of ependymal cilia. A previous study showed that STAT3 also plays a critical role in the generation of airway-ciliated cells from basal stem cells, although the mechanism is unclear (46) . Given that STAT3 is a transcription factor critical for the expression of many downstream genes, it is likely that one or more of these targets mediate the essential role of STAT3 in promoting the generation of ependymal cells and the maturation of postmitotic ependymal cells with motile cilia. Future studies are required to identify these downstream mediators.
Finally, note that SHP2 plays complicated roles in cell signaling; the cellular and molecular mechanisms responsible for Ptpn11 mutationassociated diseases and symptoms are likely to be complex. Despite having opposing effects on catalytic function, both NS-and NSMLassociated Ptpn11 mutations affect the protein-protein interactions of SHP2. Similar to NS Ptpn11 mutations (9, 11, 15, 18) , NSML-associated Table 1 . Ependymal cilia defects are proportionate to the catalytic activities of various mutant forms of SHP2. Brain sections prepared from 12-month-old mice (n = 3 mice per genotype) were immunofluorescently stained for acetyl -tubulin to mark cilia, and the ependymal cilia on the walls of ventricles were examined. NS, Noonan syndrome; NSML, NS with multiple lentigines.
Mice
Catalytic activity of mutant SHP2 Ependymal cilia Fold change in cell number Ptpn11 mutations also disrupt the intramolecular N-SH2-PTP interaction and enhance the binding between SHP2 and tyrosinephosphorylated signaling partners (9, (18) (19) (20) , due to similar changes in SHP2 protein conformation. NSML mutants function as dominant negative molecules that interfere with wild-type SHP2-mediated signaling. NSML-associated Ptpn11 inactivating mutations greatly decrease growth factor-induced activation of the RAS-ERK pathway (18) but increase AKT-mTOR signaling (19, 20) due to enhanced binding of SHP2 to insulin receptor substrate 1 and decreased ability to dephosphorylate and inactivate the downstream pathway. Conceivably, both of the deregulated catalytic activities of SHP2 mutants, combined with their enhanced protein-protein interaction capabilities, determine the differing pathological effects that distinguish NS from NSML.
MATERIALS AND METHODS
Mice
Ptpn11
E76K,C459S/+ mice were generated by gene targeting. Briefly, a full-length SHP2 E76K C459S complementary DNA was used to replace start codon ATG-containing the first exon and part of the first intron of the Ptpn11 locus in the same reading frame through homologous recombination. Ptpn11 E76K neo/+ conditional knockin mice were generated in our previous study (24) . A loxP-flanked neo cassette with a stop codon prevents the expression of the targeted allele (Ptpn11
E76K neo
). Upon deletion of neo by Cre DNA recombinase, the mutant allele (Ptpn11
E76K
) is reactivated, producing SHP2 E76K at physiological levels (24 
Immunohistochemistry and immunofluorescence staining
Paraffin sections were prepared at 5-m thickness. Before incubation in 3% H 2 O 2 in methanol for 10 min abolishing endogenous peroxidases, sections were dewaxed, rehydrated, and heated in antigen unmasking buffer [10 mM citric acid and 0.05% Tween 20 (pH 6.0)]. After blocking sections with 10% normal goat serum (NGS) in trisbuffered saline (TBS) for 30 min, primary antibodies were applied for 16 hours at 4°C. Sections were then rinsed in 1% NGS in TBS, followed by 10 min in 10% NGS, and a species-specific secondary antibody made in goat was applied for 30 min. After rinsing again as above, the species-specific peroxidase-antiperoxidase complex was applied for 1 hour at room temperature. Sections were rinsed twice in tris buffer (pH 7.6) and developed with 3′-3′-diaminobenzidine following the manufacturer's protocol. For fluorescent signals of immunoreactivity, fluorescein isothiocyanate (FITC)-or phycoerythrin-conjugated secondary antibodies were used and counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Sections were mounted with Fluoromount-G. 
Immunocomplex phosphatase assay
Whole-cell lysates (500 g) were immunoprecipitated with 2 g of an antibody recognizing SHP2. Immune complexes were washed twice with washing buffer [20 mM Hepes (pH 7.4), 50 mM NaCl, 2.5 mM MgCl 2 , 0.1 mM EDTA, and 0.05% Triton X-100] and once with phosphatase assay buffer containing 20 mM Hepes (pH 7.4), 50 mM NaCl, 2.5 mM EDTA, 5 mM dithiothreitol, and bovine serum albumin (100 g/ml). p-Nitrophenyl phosphate was then added to each sample (3.4 mM) and incubated at 30°C for 1 hour. Supernatants were transferred to 96-well plates, and absorbance at 405 nm was measured.
Neurosphere assay
The neurosphere assay was performed to determine self-renewal capacity of NSPCs, as previously described (42, 47) . Cerebral cortices dissected from E14.5 embryos were dissociated into single cells by trypsinization and mechanical dissociation. These cells were suspended and maintained in B27/neurobasal medium supplemented with bFGF (20 ng/ml), EGF (20 ng/ml), l-glutamine (1 mM), and penicillinstreptomycin in a 96-well plate at the density of 5000 cells/ml (200 l per well). After 7 days of incubation, neurospheres formed in the culture were counted under an optical microscope, and a minimum of 10 wells were counted. For the secondary neurosphere assay, primary neurospheres were collected and dissociated into a single-cell suspension and reseeded in a 96-well plate. Secondary spheres derived were enumerated 7 days later as above.
Western blotting
Neurospheres were generated, dissociated into single cells, and cultured in the presence of bFGF (20 ng/ml) for 5 days. Cells were harvested and subjected to real-time quantitative PCR analyses for mRNA abundance of bFGFR (bFGF receptor) and CNTFR (CNTF receptor). The PCR primers used were 5′-GCAGAGCATCAACTGGCTG-3′ and 5′-GGTCACGCAAGCGTAGAGG-3′ for FGFR1 and 5′-TGTC-TACACGCAGAAACACAG-3′ and 5′-CCCAGACGCTCATACT-GCAC-3′ for CNTFR. To examine bFGF and CNTF signaling, we starved cultured neurosphere cells in neural basal medium without B27 supplement and growth factors for 4 hours. Cells were then stimulated with CNTF (100 ng/ml) or bFGF (50 ng/ml) for the indicated periods of time. Cells were washed and lysed in a radioimmunoprecipitation assay buffer [50 mM tris-HCl (pH 7.4), 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 2 mM Na 3 VO 4 , leupeptin (10 g/ml), aprotin (10 g/ml), and 1 mM phenylmethylsulfonyl fluoride]. Whole-cell lysates (50 g) were resolved by SDS-polyacrylamide gel electrophoresis followed by immunoblotting with the indicated antibodies.
Neurosphere cell cycle and apoptosis analyses Neurospheres were harvested and dissociated into single cells. These cells were fixed at 4°C overnight, permeabilized, and then stained with an FITC-labeled antibody recognizing Ki67 followed by Hoechst 33342 (20 g/ml) staining. Percentages of the cells in G 0 , G 1 , and S-G 2 -M phases were quantified by fluorescence-activated cell sorting (FACS). For apoptosis analysis, neurosphere cells were stained with annexin V-FITC and 7-amino-actinomycin D using the annexin V-FITC Apoptosis Detection Kit I (BD Biosciences). Percentages of the annexin V-positive (early apoptotic cells) and annexin V/7-ADD doublepositive cells (late apoptotic cells) were quantified by FACS.
Ependymal cell differentiation
Lateral ventricular walls were dissected from newborn pups and dissociated into single cells by trypsinization and mechanical dissociation. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/GluMAX supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin in poly-l-lysine-coated flasks (50 g/ml) for 4 days. When the cells reached confluence, the flasks were closed tightly and shaken at 250 rpm for 30 min to remove weakly attached cells (mainly differentiated oligodendrocytes and neurons). The remaining cells were collected by trypsinization and resuspended in the same medium. Aliquots of the cell suspension (2 × 10 5 cells/50 l) were dropped onto poly-l-lysine coated, dried coverslips. The cells were incubated for 1 hour to allow the cells to adhere at high density. Cells on the coverslips were then cultured in tissue culture plates with the same medium for 24 hours. The medium was changed to FBS-free DMEM/GluMAX, and the cells were continuously cultured for 7 days to allow ependymal progenitors to progressively differentiate into ependymal cells. Coverslips were washed twice with phosphate-buffered saline, fixed in 4% paraformaldehyde, and processed for immunostaining with acetyl -tubulin.
The differentiated cells were also harvested and subject to qRT-PCR analyses for mRNA abundance of cell lineage markers. The PCR primers used were 5′-GCCAGCCTCAGAACAAACAG-3′ and 5′-AAGGTCTTGGGAGGGAAGAAC-3′ for Mtap2; 5′-GG-CAAATGTTCGGGCAATTCG-3′ and 5′-TCAATTTTCCGTC-CCTCTACGAT-3′ for Rbfox3; 5′-TAGACCCCAGCGGCAAC-TAT-3′ and 5′-GTTCCAGGTTCCAAGTCCACC-3′ for Tubb3; 5′-CCCTGGCTCGTGTGGATTT-3′ and 5′-GACCGATACCACTCCTCT-GTC-3′ for Gfap; 5′-TGGTTGCCCTCATTGATGTCT-3′ and 5′-CCCATCCCCATCTTCGTCC-3′ for S100b; 5′-GGACACAAT-GCACATTCAAGAAC-3′ and 5′-CCGAACCACAGACTTACAGTTT-3′ for Fabp7; 5′-CCTTGTGGTTCTTACGTTTGTTG-3′ and 5′-CGTT-GACGACATTCTCAAGCTG-3′ for Prom1; 5′-GTTGCACCGTTTC-CCGGTAA-3′ and 5′-CCCCTCTGGTGGTAGCGTTA-3′ for Cd24a. To determine the rescue effects of inhibition of ERK, AKT, and SHP2 on the ependymal differentiation of Ptpn11 E76K/+ NSPCs, we included the MAPKK1 inhibitor PD98059 (25 M), the PI3K inhibitor LY294002 (10 M), the SHP2 inhibitor #220-324 (5 and 10 M), or vehicle in the ependymal cell differentiation assay.
Electron microscopy
Brains were fixed with 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer (PB; pH 7.4) for 1 hour, and then, the ventral region of the brain, the septum, and the hippocampus were removed and fixed overnight at 4°C in the same solution. Samples were washed with 0.1 M PB three times on ice at 5-min intervals and postfixed with 1% osmium tetroxide in 0.1 M PB for 2 hours. The samples were then washed with distilled water five times on ice at 5-min intervals and dehydrated three times in an ethanol series. The ethanol was cleared with tert-butyl alcohol, and the samples were freeze-dried (ES-2030 Freeze Dryer, Hitachi), vapor-deposited with an HPC-1S osmium coater (Vacuum Devices), and examined with a field-emission scanning electron microscope (Model S4500, Hitachi).
Magnetic resonance imaging
The mouse magnetic resonance (MR) images were acquired using a high-field (9.4 T) small-animal MR scanner (Bruker BioSpin GmbH). T2-weighted MR imaging scans using a multislice multiecho sequence were acquired, producing a set of sagittal and axial images (repetition time, 1250 ms; echo time, 15 ms; flip angle, 90u; voxel size, 0.031260.031260.05 cm) while each mouse was under isoflurane-induced anesthesia at the University Hospital, Case Western Reserve University Medical Center. The animals were allowed to recover from anesthesia in their cages for at least 1 hour before imaging.
Animal behavior test
Animal behavior tests were performed at the rodent behavior core facility of Case Western Reserve University following standard protocols. The open field test was used to assess anxiety of animals (48) . The muscle strengths of forelimbs and hindlimbs of mice were measured using a commercially available grip strength meter apparatus that measures the gripping strength of mice (49) . The global neuromuscular strength and motor function were also determined by wire hang tests. In addition, the rotarod test was used to determine motor coordination (50) .
Statistical analysis
Experiments were repeated three to four times with the indicated numbers of mice (biological replicates). Data are means ± SD. Statistical significance was determined using unpaired two-tailed Student's t test. P < 0.05 is considered statistically significant.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/11/522/eaao1591/DC1 Fig. S1 . The Ptpn11 E76K mutation induces brain developmental defects with aberrant behaviors. 
